Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates

Journal of Virology

Volumn 78, Issue 9, 2004, Pages 4761-4775

  Guirakhoo, F ^a   Pugachev, K ^a   Zhang, Z ^a   Myers, G ^a   Levenbook, I ^b   Draper, K ^c   Lang, J ^d   Ocran, S ^a   Mitchell, F ^a   Parsons, M ^a   Brown, N ^a   Brandler, S ^a   Fournier, C ^d   Barrere, B ^d   Rizvi, F ^d   Travassos, A ^a   Nichols, R ^a   Trent, D ^a   Monath, T ^a  

^a Acambis   (United States)

^b Charles River Laboratories Inc ^*

^c SANOFI PASTEUR   (France)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC YELLOW FEVER DENGUE VIRUS TETRAVALENT VACCINE; CHIMERIVAX DEN; COMPLEMENTARY DNA; DENGUE VACCINE; RNA; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; IMMUNOGENICITY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROGENY; RNA TRANSCRIPTION; SEROCONVERSION; SEROTYPE; VACCINATION; VERO CELL; VIRUS ENVELOPE; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE; WILD TYPE; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANIMALS, SUCKLING; DENGUE; DENGUE VIRUS; FEMALE; MACACA FASCICULARIS; MALE; MICE; REASSORTANT VIRUSES; RECOMBINATION, GENETIC; VIRAL VACCINES; WEST NILE VIRUS VACCINES; YELLOW FEVER; YELLOW FEVER VIRUS;

EID: 4444260806     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.9.4761-4775.2004     Document Type: Article

References (52)

1. Arroyo, J., C. A. Miller, J. Catalan, and T. P., Monath. 2001. Yellow fever vector live-virus vaccines: West Nile vaccine development. Trends Mol. Med. 7:329-377.
2. Blaney, J. E., G. G. Manipon, C. Y. Firestone, D. H. Johnson, C. T. Hanson, B. R. Murphy, and S. S. Whitehead. 2003. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine 21:4317-4327.
3. Brandriss, M. W., J. J. Schlesinger, E. E. Walsh, and M. Briselli. 1986. Lethal 17D yellow fever encephalitis in mice. I Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J. Gen. Virol. 67:229-234.
4. Butrapet, S., J. Rabablert, S. Angsubhakorn, W. Wiriyarat, C. Huang, R. Kinney, S. Punyim, and N. Bhamarapravati. 2002. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys. Southeast Asian J. Trop. Med. Public Health 33:589-599.
5. Caufour, P. S., M. C. A. Mutta, A. M. Y. Yamamura, S. Vazquez, I. I. Ferreira, A. V. Jabor, M. C. Bonaldo, M. S. Freire, and R. Galler. 2001. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res. 79:1-14.
6. Centers for Disease Control and Prevention. 2002. Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. Morb. Mortal. Wkly. Rep. 51:989-993.
7. Chambers, T. J., A. Nestorowicz, P. W. Mason, K. H. Eckels, and C. M. Rice. 1999. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73:3095-3101.
8. Chambers, T. J., Y. Liang, D. A. Droll, J. J. Schlesinger, A. D. Davidson, P. J. Wright, and X. Jiang. 2003. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J. Virol. 77:3655-3668.
9. Durbin, A. P., R. A. Karron, W. Sun, D. W. Vaughn, M. J. Reynolds, J. R. Perreault, B. Thumar, R. Men, C. J. Lai, W. R. Elkins, R. M. Chanock, B. R. Murphy, and S. S. Whitehead. 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 3D nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65:405-413.
10. Fox J. P., and H. A. Penna. 1943. Behavior of 17D yellow fever virus in rhesus monkeys. Relation to substrain, dose and neural or extraneural inoculation. Am. J. Hyg. 38:152-172.
11. Gagnon, S. J., W. Zeng, I. Kurane, and F. A. Ennis. 1996. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones. J. Virol. 70:141-147.
12. Gibbons, R. V., and D. W. Vaughn. 2002. Dengue: an escalating problem. Br. Med. J. 324:1563-1566.
13. Gubler, D. J. 1997. Dengue and dengue hemorrhagic fever: its history and resurgence as a global public health problem, p. 1-22. In D. J. Gubler and G. Kuno (ed.), Dengue and dengue hemorrhagic fever. CABI Publishing, New York, NY.
14. Guirkahoo, F., J. Arroyo, K. V. Pugachev, C. Miller, Z.-X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratterree, and T. P. Monath. 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75:7290-7304.
15. Guirakhoo, F., K. Pugachev, J. Arroyo, C. Miller, Z.-X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Draper, and T. P. Monath. 2002. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298:146-159.
16. Guirakhoo, F., R. Weltzin, T. J. Chambers, Z.-X. Zhang, K. Soike, M. Ratterree, J. Arroyo, K. Georgakopoulos, J. Catalan, and T. P. Monath. 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol. 74:5477-5485.
17. Guirakhoo, F., Z.-X. Zhang, T. J. Chambers, S. Delagrave, J. Arroyo, A. D. T. Barrett, and T. P. Monath. 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax™-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257:363-372.
18. Halstead, S. B. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481.
19. Hardy, J. L. 1988. Susceptibility and resistance of vector mosquitoes, p 87-126. In T. P. Monath (ed.). The arboviruses: ecology and epidemiology, vol. 1. CRC, Inc., Boca Raton, Fla.
20. Huang, C. Y., S. Butrapet, K. R. Tsuchiya, N. Bhamarapravati, D. J. Gubler, and R. M. Kinney. 2003. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol. 77:11436-11447.
21. Jan, J.-T., B.-H. Chen, S.-H. Ma, C.-I. Liu, H.-P. Tsai, H.-C. Wu, S.-Y. Jiang, K.-D. Yuang, and M.-F. Shaio. 2000. Potential dengue virus-triggered apoptotic pathway in human neuroblastoma cells: arachidonic acid, superoxide anion, and NF-kappaB are sequentially involved. J. Virol. 74:8680-8691.
22. Johnson, B. W., T. V. Chambers, M. B. Crabtree, F. Guirakhoo, T. P. Monath, and B. R. Miller. 2004. Analysis of the replication kinetics of the ChimeriVax™-DEN 1,2,3,4 tetravalent virus mix in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am. J. Trop. Med. Hyg. 70:89-97.
23. Kanesa-thasan, N., W. Sun, G. Kim-Ahn, S. Van Albert, J. R. Putnak, A. King, B. Raengsakulsrach, H. Christ-Schmidt, K. Gilson, J. M. Zahradnik, D. W. Vaughn, B. L. Innis, J.-F. Saluzzo, and C. H. Hoke. 2001. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19:179-188.
24. Kliks, S. C., A. Nisalak, W. E. Brandt, L. Wahl, and D. S. Burke. 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:444-451.
25. Kochel, T. J., D. M. Watts, S. B. Halstead, C. G. Hayes, A. Espinoza, V. Felices, R. Caceda, C. T. Bautista, Y. Montoya, S. Douglas, and K. L. Russell. 2002. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 360:310-312.
26. Levenbook, I. S., L. J., Pelleu, and B. L. Elisberg. 1987. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J. Biol. Stand. 15:305-313.
27. - cytotoxic T-cell clones. J. Virol. 68:3283-3288.
28. Livingston, P. G., I. Kurane, L. C. Dai, Y. Okamoto, C. L. Lai, R. Men, S. Karaki, M. Takiguchi, and F. A. Ennis. 1995. Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities. J. Immunol. 154:1287-1295.
29. Lum, L. C., S. K. Lam, Y. S. Choy, R. George, and F. Harun. 1996. Dengue encephalitis: a true entity? Am. J. Trop. Med. Hyg. 54:256-259.
30. Marchevsky, R. S., M. S. Freire, E. S. Coutinho, and R. Galler. 2003. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 316:55-63.
31. Martin, M., L. H. Weld, T. F. Tsai, G. T. Mootrey, R. T. Chen, M. Niu, M. S. Cetron, and the GeoSentinel Yellow Fever Working Group. 2001. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg. Infect. Dis. 7:945-951.
32. + cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J. Clin. Investig. 98:1684-1691.
33. McBride, W. J., and H. Bielefeldt-Ohmann. 2000. Dengue viral infections; pathogenesis and epidemiology. Microbes Infect. 2:1041-1050.
34. Monath, T. P. 1994. Dengue-the risk to developed and developing countries. Proc. Natl. Acad. Sci. USA 91:2395-2400.
35. Monath, T. P., F. Guirakhoo, R. Nichols, S. Yoksan, R. Schrader, C. Murphy, P. Blum, S. Woodward, K. McCarthy, D. Mathis, C. Johnson, and P. Bedford. 2003. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188:1213-1230.
36. Monath, T. P., I. Levenbook, K. Soike, Z.-X. Zhang, M. Ratterree, K. Draper, A. D. T. Barrett, R. Nichols, R. Weltzin, J. Arroyo, and F. Guirakhoo. 2000. Chimeric yellow fever 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol. 74:1742-1751.
37. Monath, T. P., J. Arroyo, I. Levenbook, Z.-X. Zheng, J. Catalan, K. Draper, and F. Guirakhoo. 2002. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J. Virol. 76:1932-1943.
38. Monath, T. P., K. McCarthy, P. Bedford, C. T. Johnson, R. Nichols, S. Yoksan, R. Marchesani, M. Knauber, K. H. Wells, J. Arroyo, and F. Guirakhoo. 2002. Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20:1004-1018.
39. Monath, T. P., K. Soike, I. Levenbook, Z.-X. Zhang, J. Arroyo, S. Delagrave, G. Myers, A. D. Barrett, R. E. Shope, M. Ratterree, T. J. Chambers, and F. Guirakhoo. 1999. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 17:1869-1882.
40. Nathanson, N., and B. Harrington. 2000. Experimental infection of monkeys with Langat virus. II. Turnover of circulating virus. Rev. Med. Virol. 10:207-215.
41. National Institutes of Health. 1998. Guide for the care and use of laboratory animals, rev. ed. Department of Health and Human Services publication (NIH) 85-23. National Institutes of Health, Bethesda, Md.
42. Phillpotts, R. J., J. R. Stephenson, and J. S. Porterfield. 1987. Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus. Brief report. Arch. Virol. 93:295-301.
43. Pletnev, A. G., M. Bray, K. A. Hanley, J. Speicher, and R. Elkins. 2001. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes. Virology 75:8259-8267.
44. Pletnev, A. G., R. Putnak, J. Speicher, E. J. Wagar, and D. W. Vaughn. 2002. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl. Acad. Sci. USA 99:3036-3041. (Erratum, 99:7184.)
45. Pugachev, K. V., F. Guirakhoo, S. W. Ocran, F. Mitchell, M. Parsons, C. Penal, S. Girakhoo, S. O. Pougatcheva, J. Arroyo, D. W. Trent, and T. P. Monath. 2004. High fidelity of yellow fever virus RNA polymerase. J. Virol. 78:1032-1038.
46. Rigau-Pérez, J. G., G. G. Clark, D. J. Gubler, P. Reiter, E. J. Sanders, and A. V. Vorndam. 1998. Dengue and dengue haemorrhagic fever. Lancet 352: 971-977.
47. Sabchareon, A., J. Lang, P. Chanthavanich, S. Yoksan, R. Forrat, P. Attanath, C. Sirivichayakui, K. Pengsaa, C. Pojjaroen-Anat, W. Chokejindachai, A. Jagsudee, J.-F. Saluzzo, and N. Bhamarapravati. 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccine in Thai adult volunteers: role of serotype concentration, ratio and multiple doses. Am. J. Trop. Med. Hyg. 66:264-272.
48. van der Most, R. G., K. Murali-Krishna, R. Ahmed, and J. H. Strauss. 2000. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J. Virol. 74:8094-8101.
49. Whitehead, S. S., K. A. Hanley, J. E. Blaney, L. E. Gilmore, W. R. Elkins, and B. R. Murphy. 2003. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 21:4307-4316.
50. World Health Organization. 1998. Requirements for yellow fever vaccine (requirements for biological substances no. 3.). W.H.O. Tech. Rep. Ser. 872:30-65.
51. World Health Organization. 2002. WHO fact sheet 117. World Health Organization, Geneva, Switzerland.
52. Zhang, M., M. Wang, S. Jiang, and W. Ma. 1989. Passive protection of mice, goats, and monkeys against Japanese encephalitis with monoclonal antibodies. J. Med. Virol. 29:133-138.